COVID-19 triaging using the inflammatory biomarker suPAR

COVID-19 triaging using the inflammatory biomarker suPAR https://www.virogates.com/wp-content/uploads/2021/01/speakers-Linkedin-1200x627-1.jpg The prognostic biomarker suPAR is currently used across various hospitals in Europe to manage COVID-19 patients. The admission suPAR level is an early indicator for the risk of developing severe respiratory failure and requiring mechanical ventilation*. Using admission suPAR levels for COVID-19 patients, physicians may identify low-risk patients for early discharge to reduce the pressure on COVID-19 hospitals, i.e., at emergency departments and in intensive care units 4,5. Furthermore, physicians may identify high-risk patients for early treatment. COVID-19 hospitals using suPAR for risk stratification may experience: Improved patient care with fewer unnecessary admissions, fewer re-admissions, early treatment intervention, and shorter length-of-stay Empowered clinical staff with more information to make confident decisions reducing stress and uncertainty Reduced healthcare costs suPAR is a naturally occurring protein measurable in all humans reflecting immune activation. The protein is associated with inflammation and adverse outcomes across life threatening diseases. suPAR can be measured in clinical routine using the suPARnostic® TurbiLatex product that fits existing hospital work flows and instruments. suPARnostic® TurbiLatex is validated for use on clinical chemistry analysers from Roche Diagnostics, Siemens Healthineers, and Abbott. Sign up for our webinar Catch COVID-19 - Improve your triage The suPAR biomarker predicts risk of complications in COVID-19 patients On the 4th of February at 14:00 CET you can learn more about the suPAR biomarker and how hospitals are using it today in their triaging and risk stratification process.PHNjcmlwdCBhc3luYyBpZD0iZGVtaW8tanMiIHR5cGU9InRleHQvamF2YXNjcmlwdCIgc3JjPSJodHRwczovL2Nkbi5kZW1pby5jb20vZGlzdC9lbWJlZC5idW5kbGUuanMiPjwvc2NyaXB0PiA8c3BhbiBjbGFzcz0iZGVtaW8tZW1iZWQtcmVnaXN0cmF0aW9uIiBkYXRhLWhhc2g9ImEzdDlIMHJZVkVha1M5blQiIGRhdGEtYXBpPSJhcGkvdjEiIGRhdGEtYmFzZS11cmk9Imh0dHBzOi8vbXkuZGVtaW8uY29tLyIgZGF0YS1mb3JtLXdpZHRoPSIxMDAlIiBkYXRhLWNvbG9yPSIjMzhhYTM0IiBkYXRhLXRleHQ9IlNJR04gVVAiID48L3NwYW4+IA How to interpret suPAR results in the COVID-19 department 6 suPAR level above 6 ng/ml Supports hospitalization High risk of requiring mechanical ventilation suPAR levels between 4 ng/ml and 6 ng/ml support further attention taking other clinical findings and laboratory testing into account "suPAR can be a strong tool for the much-needed early risk stratification of patients with COVID-19." Prof. Ove Andersen, MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark. suPAR News Vol. 3, June 2020 COVID-19 patient outcome Need for mechanical ventilation Source: Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 24, 187 (2020). Do you want to be contacted by a specialist? We will get back to you within 24 hours on weekdays. "It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital." Prof. Ove Andersen, MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark suPAR News Vol. 3, June 2020 Prediction of severe respiratory failure (SRF) and the need for mechanical ventilation for COVID-19 patients Cut-off predictor of SRF suPAR level ≥ 6 ng/ml Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Rovina N et al. Crit Care. 2020 4(1):187. A recent study by Rovina et al1 evaluated whether the suPAR-level at the time of admission could identify patients who would likely develop SRF within the first-coming 14 days. It appeared that a suPAR-level ≥ 6 ng/ml, a cut-off point identified using ROC-analysis, was a strong predictor for developing SRF and requiring ventilation within a relatively short period. This was confirmed in an international multicenter study showing that very few COVID-19 patients with suPAR below 4.6 ng/ml developed respiratory failure (N3, 2.6%) compared to patients with suPAR above 6.86 ng/ml (N53, 44.9%)2. Prediction of acute kidney injury (AKI) and requirement for dialysis for COVID-19 patients Patients infected with COVID-19 often develop AKI and many of those patients require dialysis. In a recent paper, Azam et al investigated the link between a patient’s suPAR level and incidence of in-hospital AKI2. It appeared that in patients hospitalized with COVID-19, the suPAR-level at the time of admission was a strong predictor of developing in-hospital AKI and the need for dialysis. The higher the suPAR-level, the more severe the outcome. For patients admitted with a suPAR-level 6.86 ng/ml, there was a 45.8% incidence of AKI with 16.1% of those patients requiring dialysis2. Cut-off AKI incidence increases with suPAR tertiles First tertile: suPAR 6.86 ng/ml results in 45.8% incidence of AKI and 16,1% requiring dialysis Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU et al. J Am Soc Nephrol. 2020 * suPAR values should be used in conjunction with clinical findings and the results of other laboratory parameters. suPAR values alone are not indicative of the need for mechanical ventilation. 1. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Rovina N et al. Crit Care. 2020 4(1):187. (LINK: https://pubmed.ncbi.nlm.nih.gov/32354367/ 2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU et al. J Am Soc Nephrol. 2020 (LINK: https://pubmed.ncbi.nlm.nih.gov/32963090/ 3. Soluble Urokinase-Guided Anakinra To Prevent Respiratory Failure In COVID-19: A Single-Arm Trial. Kyriazopoulou E et al. (preprint, link to be provided when available) 4. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Chalkias A et al. Mol Diagn Ther. 2020 (5):517-521. (LINK: https://pubmed.ncbi.nlm.nih.gov/32613288/ 5. COVID-19 and pneumonia: a role for the uPA/uPAR system. D'Alonzo D et al. Drug Discov Today. 2020 (8):1528-1534. Review. (LINK: https://pubmed.ncbi.nlm.nih.gov/32562843/ Want to know more about suPAR? Learn about suPAR